检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:周莉 张志峰 张婵 Zhou Li;Zhang Zhifeng;Zhang Chan(Intensive are Unit,Hospital of Traditional Chinese Medicine of Shangqiu City,Shangqiu 476000,China;不详)
出 处:《中国循证心血管医学杂志》2023年第3期361-363,共3页Chinese Journal of Evidence-Based Cardiovascular Medicine
摘 要:目的观察曲美他嗪治疗不稳定型心绞痛(UAP)疗效及对基质金属蛋白酶[MMP(MMP-1、MMP-2、MMP-9、MMP-12)]的影响。方法2020年4月至2021年9月于商丘市中医院就诊的91例UAP患者,随机分为对照组(n=45)和治疗组(n=46),对照组予以常规治疗,治疗组加用曲美他嗪,两组均治疗8周。比较两组临床疗效及血清MMP-1、MMP-2、MMP-9、MMP-12,采用WHO生活质量测定量表(WHOQOL-100)评价生存质量。结果治疗组总有效率91.30%,明显高于对照组的73.33%,差异有统计学意义(P<0.05)。治疗后,两组血清MMP-1、MMP-2、MMP-9含量均降低,WHOQOL-100量表评分升高(P<0.05);与对照组相比,治疗组均优于对照组(P<0.05)。结论曲美他嗪对UAP有较好治疗作用,可降低患者MMP含量,提高生存质量。Objective To observe the curative effect and influence of trimetazidine on unstable angina pectoris(UAP),matrix metalloproteinase-1(MMP-1),MMP-2 and MMP-9.Methods UAP patients(n=91)were chosen from Hospital of Traditional Chinese Medicine of Shangqiu City from Apr.2020 to Sept.2021,and all patients were randomly divided into control group(n=45)and treatment group(n=46).All groups were treated for 8 weeks,and clinical efficacy and levels of serum MMP-1,MMP-2,MMP-9 and MMP-12 were compared between 2 groups.The quality of life(QOL)was reviewed by using Quality of Life made by WHO(WHOQOL-100).Results The total effective rate was 91.30%in treatment group and 73.33%in control group(P<0.05).After treatment,the levels of MMP-1,MMP-2 and MMP-9 decreased and scores of WHOQOL-100 increased in 2 groups(P<0.05),and all results were better in treatment group than those in control group(P<0.05).Conclusion Trimetazidine has a good therapeutic effect on UAP and can reduce MMPs levels and improve quality of life.
关 键 词:曲美他嗪 不稳定型心绞痛 基质金属蛋白酶 生存质量
分 类 号:R541.4[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.70